| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Competitive antagonism of AR; inhibits growth of VCaP prostate cancer cell line. Does not show agonistic activity towards pregnane X receptor (PXR). Induces autophagy in neuro cells; promotes α-Syn degradation. Improves mitochondrial function and extends healthspan in model organisms. Very low ability to cross the blood-brain barrier. Inhibits monoamine oxidase.
|
|---|---|
| ln Vitro |
Improves mitochondrial function and metabolic parameters, and extends healthspan in model organisms. Induces transient mitochondrial depolarization and strong mitophagy response. No specific disease-model in vivo data identified in available search results.
|
| ln Vivo |
AR competitive binding assay: recombinant AR ligand-binding domain incubated with Harmol and radiolabeled androgen (e.g., [³H]-R1881); bound radioactivity measured. High-content screening using U2OS reporter cell models for AR transactivation. Mitochondrial function assays: Seahorse analyzer for oxygen consumption rate; mitophagy assessed by mito-QC or mt-Keima reporters.
|
| Enzyme Assay |
VCaP prostate cancer cells treated with Harmol (0.1-50 µM); cell growth assessed by MTT or SRB. Neuro cells (SH-SY5Y, primary neurons) treated with Harmol; autophagy markers (LC3-II, p62) by Western blot; α-Syn degradation measured by Western blot. U2OS reporter cells for AR activity.
|
| Cell Assay |
No specific in vivo animal protocol identified for Harmol in available search results. Potential models include prostate cancer xenografts, neurodegeneration models (α-synucleinopathy), or aging/healthspan models (C. elegans, mice), but published protocols specifically for Harmol were not identified.
|
| References |
| Molecular Formula |
C12H10N2O.HCL
|
|---|---|
| Exact Mass |
234.056
|
| CAS # |
40580-83-4
|
| Related CAS # |
487-03-6 (Parent)
|
| PubChem CID |
94507
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
552.7ºC at 760 mmHg
|
| Flash Point |
255ºC
|
| LogP |
3.532
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
16
|
| Complexity |
516
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
Cl.O=C1C=CC2=C3C=CNC(C)=C3NC2=C1
|
| InChi Key |
RBOUBJPHXSVUTH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H10N2O.ClH/c1-7-12-10(4-5-13-7)9-3-2-8(15)6-11(9)14-12;/h2-6,13-14H,1H3;1H
|
| Chemical Name |
1-methyl-2,9-dihydropyrido[3,4-b]indol-7-one;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
